News

Bispecific Antibody Plus EGFR Inhibitor in EGFR-Mutant Lung Cancer

EGFR-Mutated NSCLC: MRD Detection and Adjuvant Osimertinib

Refining Treatment of Oligometastatic NSCLC Is a Work in Progress

University of Utah Researchers Receive $2.6 Million Grant to Study Lung Tumor Biomechanics

Quality-of-Life Data Support Pembrolizumab’s Role in Early-Stage NSCLC

Use of Icotinib After Adjuvant Chemotherapy in EGFR-Mutated NSCLC

Health-Related Quality-of-Life Data From ALINA on Alectinib in NSCLC

Geriatric Assessment: Determining Optimal Treatment for Older Patients With NSCLC

Patient Education Initiative for Veterans With Non–Small Cell Lung Cancer

Bilobectomy vs Middle Lobe–Sparing Sleeve Resection for Central NSCLC of the Right Lower Lobe

Amivantamab Plus Lazertinib in High-Risk Subgroups With Advanced NSCLC

ASCO 2024: Study Analysis Focuses on Nodal Status With Neoadjuvant Nivolumab in Stage III NSCLC

ASCO 2024: Tumor-Treating Fields Therapy for Patients With NSCLC and Brain Metastases

Patient-Reported Outcomes: Wedge Resection vs Uniportal Thoracoscopic Segmentectomy for Peripheral NSCLC

ASCO 2024: New Antibody-Drug Conjugate Under Study in First Line for Advanced NSCLC

ASCO 2024: Air Pollution, Gene-Environment Interactions, and Risk of NSCLC in Nonsmokers

ASCO 2024: Novel KRAS G12C Inhibitor Plus Pembrolizumab for Advanced, Mutant NSCLC

ASCO 2024: CodeBreaK 101 Update on Sotorasib Plus Chemotherapy for Advanced NSCLC

ASCO 2024: Updated IMpower010 Survival Analysis of Atezolizumab in PD-L1–Positive NSCLC

ASCO 2024: Adagrasib vs Docetaxel in KRAS G12C–Mutated NSCLC

ASCO 2024: Subcutaneous vs Intravenous Amivantamab Combined With Lazertinib in NSCLC

ASCO 2024: Early Results From EVOKE-01 of Sacituzumab Govitecan in Metastatic NSCLC

ASCO 2024: Is Telehealth-Based Early Palliative Care Feasible in Advanced NSCLC?

ASCO 2024: Osimertinib After Chemoradiotherapy for EGFR-Mutated NSCLC

ASCO 2024: Long-Term Outcomes With Lorlatinib vs Crizotinib in ALK-Positive NSCLC

Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy for Resectable NSCLC

STK11 Mutations and Immunotherapeutic Efficacy in NSCLC

Case Study: Pathologic Complete Response After Triple-Induction Therapy for NSCLC

Insights Into NSCLC Management: Comprehensive Study Findings From South Korea

Can Oligoprogressive NSCLC Be Treated With Radiotherapy After Immunotherapy?

Does Thoracic Radiotherapy Induce Changes in Cardiac Morphology and Function?

Can Novel Methylation Biomarkers Enhance Lung Cancer Diagnosis via Bronchial Washing Samples?

ASCO Plenary Series: Phase II Study of Glecirasib in KRAS G12C–Mutated NSCLC

Molecular and Radiographic Biomarkers of Lung Cancer in Never-Smokers

AACR 2024: Can Ferroptosis Induction Overcome Chemoresistance in NSCLC?

AACR 2024: Indoor Aerosol Carcinogens and Nonsmoking-Related Lung Cancer

Alectinib Approved by FDA as Adjuvant Therapy for ALK-Positive NSCLC

AACR 2024: Estrogen Metabolites and Lung Cancer Among Never-Smokers

Does Vaping, in Addition to Smoking, Increase the Risk for Lung Cancer?

AACR 2024: New Data Reveal Mutagenic Forces May Cause Lung Cancer in Nonsmokers

Can Deep Learning Algorithm Predict Brain Metastasis in Patients With Lung Cancer?

Researchers Develop Novel Pan-Cancer Biomarker to Assess Tumor Microenvironment

SSO 2024: Is Image-Based Obesity Linked to Metabolic Pathway Alterations in NSCLC?

DNA Methylation: Researchers in Search of a Better Way to Screen for Lung Cancer

Are Immune-Related Adverse Events Associated With Overall Survival in NSCLC?

Understanding Acquired Resistance to Immunotherapy for NSCLC: Genomic and Immunophenotypic Insights

Updated Data on Entrectinib in NTRK Fusion–Positive NSCLC

ESMO Virtual Plenary: Neoadjuvant Tislelizumab Plus Chemotherapy and Adjuvant Tislelizumab for NSCLC

Racial Disparities in NSCLC: Biologic and Social Factors in Diagnosing Hispanic Individuals

FDA Approves Bispecific Antibody Plus Chemotherapy for EGFR Exon 20 Insertion–Mutated NSCLC

Using Deep Learning–Based Framework to Classify Lung Cancer Histology and Prognosis

FDA Brief: Breakthrough Therapy Designation Granted to Two Tyrosine Kinase Inhibitors in NSCLC

CheckMate 722: Final Results With Nivolumab Plus Chemotherapy in Metastatic NSCLC

Osimertinib With Chemotherapy Granted FDA Approval for EGFR-Mutated NSCLC

Cardiac Health and Lung Cancer Treatments: A Complex Balancing Act for Oncologists

FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations

Patient Age and Sex: Indicators for Segmentectomy vs Lobectomy in Pure-Solid NSCLC?

Is Medicaid Expansion Under the ACA Linked to Better Survival After Surgery for NSCLC?

STS 2024: Risk Factors and Predictors of VTE in Patients Undergoing Lung Cancer Surgery

Survey Says Medical Oncologists Favor More Research on Combination Therapies for Advanced NSCLC

NTRK Fusions in NSCLC: Improving Detection With Novel Methodology

DICER1 Hotspot Mutations in NSCLC: Clinical Implications for Genetic Testing

Using Machine Learning and CT Radiomics to Predict Brain Metastasis in Patients With NSCLC

Evaluating the Risk of Long QT Syndrome Risk in Older Patients Treated With Osimertinib for NSCLC

Could Adjuvant Chemotherapy Improve Survival Among High-Risk Patients With Stage IB NSCLC?

Targeted Therapies for NSCLC: Pathways to Fertility and Motherhood

Is First-Line Immunotherapy Efficacy Impacted by Race or Ethnicity in Advanced NSCLC?

Concurrent Chemoradiation With Dose-Escalation Ablative Radiotherapy for Unresectable NSCLC

Study Finds Clinical Benefit of Repotrectinib in ROS1 Fusion–Positive NSCLC